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D
uring a visit to Japan years ago, I was 
impressed that most sumo wrestlers 
stated during interviews after their 
victories, ‘Now we must work even 
harder.’ This sentiment describes the feeling of 
the new editorial team after the 40th birthday 
jubilee of Kidney International in January 2012, 
when it succeeded the editorial team led by Qais 
Al-Awqati.1 Under his leadership, KI, the flagship 
journal of the International Society of Nephrology, 
has become one of the two leading nephrology 
journals worldwide, a position that the new edito-
rial team will work hard to 
maintain and strengthen 
by publishing the newest 
and most exciting develop-
ments covering all aspects 
of nephrology. In order 
to achieve this goal, we 
have expanded the edito-
rial team to achieve broad 
thematic and geographic 
diversification. The team 
includes associate editors 
Daniel Cattran (Toronto, 
Canada), covering clinical 
glomerular diseases and 
research; P. Toby Coates 
(Adelaide, Australia), 
for immunology and 
transplantation; Andrew 
Davenport (London, UK), 
for dialysis and ICU neph-
rology; Tilman Drüeke 
(Paris/Amiens, France), 
for the broad range of 
comorbidity and complications of chronic renal 
diseases; Masaomi Nangaku (Tokyo, Japan), for 
studies on clinical and experimental aspects of 
the generation and progression of renal diseases, 
including the role of genetics; Mark Okusa (Char-
lottesville, VA, USA), for experimental and clinical 
acute kidney injury and for fluid, electrolyte, and 
acid–base problems; Jai Radhakrishnan (New 
York, NY, USA), for the latest clinical studies and 
the Nephrology Image and Make Your Diagnosis 
sections of KI; and Maria Pia Rastaldi (Milan, 
Italy), for clinical and experimental pathology 
and cell biology; and finally, Michael Ross (New 
York) as deputy editor, covering molecular aspects 
of kidney disease. Hypertension, diabetic kidney 
disease, and renal physiology and development 
are topics covered by several members of the 
editorial team. I have the privilege of coordinat-
ing this wonderful team in our efforts to provide 
you with enjoyable and enlightening reading of 
cutting-edge nephrology papers.
To achieve our goals, the editorial team has a 
weekly video-telephone conference, where we dis-
cuss all the papers submitted to KI, presently an 
impressive 1500+ per year 
and continuously increas-
ing. We take seriously our 
motto, ‘now we must work 
even harder,’ as some of the 
editors join the conference 
at 6 am while for others it 
will already be 10 or 11 pm 
in their parts of the world. 
We debate which submis-
sions to choose for pub-
lication and how to help 
the authors to improve 
their papers. For this dif-
ficult task, we rely heavily 
on the help of our expert 
reviewers, who generously 
devote large amounts of 
their time and efforts to 
KI. This selfless contribu-
tion of the nephrology 
community toward our 
nephrology journals can-
not be overstated, as the 
review process remains essential in guiding us 
to make the best and fairest choices, debatably a 
mission not always achieved.
Over the next several years, we will strive to 
maintain an optimal balance between clinical, 
experimental, and basic studies while expanding 
our focus on the most exciting translational kid-
ney disease research. Rapid advances in research 
methodology, especially in immunology, genetics, 
and molecular and cellular biology, are revolution-
izing our understanding of normal kidney physiol-
ogy and are elucidating novel mechanisms of renal 
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diseases. Current and future reviews in KI will 
be devoted to important aspects of translational 
nephro logy. For example, the advent of improved 
gene arrays and the next generation, whole genome 
sequencing, may uncover novel DNA mutations 
that contribute not only to Mendelian inheritance 
of specific hereditary kidney diseases but also to 
predisposing factors for the generation or pro-
gression of kidney diseases.2,3 The power of these 
approaches is clearly demonstrated by the recent 
discoveries of numerous genes involved in familial 
forms of glomerular diseases and the identification 
of polymorphisms in the ApoL1 gene as predispos-
ing patients of African ancestry to the develop-
ment of focal segmental glomerulosclerosis. Other 
important examples include the clarification of the 
molecular basis for the roles of phosphate, FGF23, 
and vitamin D in the progression of chronic kidney 
disease (CKD) and its complications.4,5 Successful 
translational research is further exemplified by the 
recent identification of the M-type phospholipase 
A2 receptor as the target antigen in membranous 
nephropathy, which followed decades of painstak-
ing immunological experimental work.6 It is our 
hope that these advances will lead to novel thera-
peutic approaches that ultimately improve the 
health of our patients.
We are expanding our series on translational 
medicine by publishing reviews detailing the roles 
of epigenetic modifications and microRNAs as 
modifiers of gene expression.7 These may con-
tribute significantly to the development and 
progression of such devastating diseases as dia-
betic nephropathy, the loss of renal function in the 
elderly, and nutritional aspects of CKD and their 
vascular and musculoskeletal complications.
Although inhibition of the renin–angiotensin–
aldosterone system can slow the progression of 
diabetic nephropathy and many forms of CKD, 
unfortunately this approach has only modestly 
reduced the eventual development of end-stage 
renal disease, requiring dialysis or transplantation 
as renal replacement therapy. Similarly, despite 
advances in immunosuppressive therapy, which 
have made acute allograft rejection a relatively 
uncommon complication, attempts to reduce 
allograft loss due to slowly progressive transplant 
nephropathy have been far less successful. In short, 
progression of all forms of CKD will require new 
forms of preventive and therapeutic interventions. 
Hopefully, improved understanding of the molecu-
lar and cellular pathways contributing to disease 
pathogenesis will provide us with novel therapies, 
the ultimate goal of translational medicine. These 
statements are also applicable to acute kidney 
injury, for which we still lack successful therapeutic 
and, even more importantly, preventive measures. 
To this end, KI is currently publishing a series of 
articles devoted to ICU nephrology.
Finally, I would like to mention the enormous 
problems facing nephrology in emerging coun-
tries, which often lack the financial resources and 
infrastructure to allow implementation of even 
the most basic therapies for kidney diseases.8 KI 
and KI Supplements, as journals of the Interna-
tional Society of Nephrology, are committed to 
covering important aspects of global medicine 
concerning kidney disease.
In summary, the editorial team of KI remains 
devoted to the goal of maintaining KI as a leading 
journal for nephrology, a goal that we can reach 
only if clinical and basic researchers working in 
nephrology continue to submit their best papers 
to KI. ‘Now we all must work even harder.’
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